MX353074B - Mutantes profactor de crecimiento del nervio (ngf) novedosos y usos de los mismos en la produccion de factor de crecimiento del nervio beta. - Google Patents

Mutantes profactor de crecimiento del nervio (ngf) novedosos y usos de los mismos en la produccion de factor de crecimiento del nervio beta.

Info

Publication number
MX353074B
MX353074B MX2014007317A MX2014007317A MX353074B MX 353074 B MX353074 B MX 353074B MX 2014007317 A MX2014007317 A MX 2014007317A MX 2014007317 A MX2014007317 A MX 2014007317A MX 353074 B MX353074 B MX 353074B
Authority
MX
Mexico
Prior art keywords
ngf
beta
production
prongf
prongf mutant
Prior art date
Application number
MX2014007317A
Other languages
English (en)
Other versions
MX2014007317A (es
Inventor
Lorey Susan
Janowski Bernhard
Pultke Heiko
Kathmann Daniela
Parthier Antje
Anton Andreas
Original Assignee
Wacker Chemie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47428641&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX353074(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wacker Chemie Ag filed Critical Wacker Chemie Ag
Publication of MX2014007317A publication Critical patent/MX2014007317A/es
Publication of MX353074B publication Critical patent/MX353074B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención se refiere a un mutante proNGF, caracterizado porque el sitio de escisión d ela proteasa R1SK3R4 se sustituye al menos en las posiciones R1 K3 que corresponden a las posiciones 101 y 103 de la secuencia de proNGF de tipo natural humano (SEQ ID N: 1); en donde el aminoácido en la posición 101 de la secuencia de proNGF de tipo natural humano (SEQ ID NO:1) se sustituye por Valina, en la posición 103 por Alanina, y en donde el aminoácido en la posición 102 es Serina y el aminoácido en la posición 104 es Arginina, o en donde el mutante proNGF comprende la secuencia de aminoácido de SEQ ID No: 5.
MX2014007317A 2011-12-19 2012-12-19 Mutantes profactor de crecimiento del nervio (ngf) novedosos y usos de los mismos en la produccion de factor de crecimiento del nervio beta. MX353074B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11194208 2011-12-19
PCT/EP2012/076251 WO2013092776A1 (en) 2011-12-19 2012-12-19 Novel prongf mutants and uses thereof in the production of beta-ngf

Publications (2)

Publication Number Publication Date
MX2014007317A MX2014007317A (es) 2014-11-25
MX353074B true MX353074B (es) 2017-12-19

Family

ID=47428641

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014007317A MX353074B (es) 2011-12-19 2012-12-19 Mutantes profactor de crecimiento del nervio (ngf) novedosos y usos de los mismos en la produccion de factor de crecimiento del nervio beta.
MX2017012894A MX370861B (es) 2011-12-19 2012-12-19 Mutantes profactor de crecimiento del nervio (ngf) novedosos y usos de los mismos en la producción de factor de crecimiento del nervio beta.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017012894A MX370861B (es) 2011-12-19 2012-12-19 Mutantes profactor de crecimiento del nervio (ngf) novedosos y usos de los mismos en la producción de factor de crecimiento del nervio beta.

Country Status (28)

Country Link
US (3) US9617322B2 (es)
EP (2) EP2672984B1 (es)
JP (4) JP6039146B2 (es)
KR (2) KR20160120788A (es)
CN (2) CN104203264B (es)
AU (1) AU2012357052B2 (es)
BR (1) BR112014014913B1 (es)
CA (1) CA2859262C (es)
CY (2) CY1117016T1 (es)
DK (2) DK2672984T3 (es)
EA (1) EA031333B1 (es)
ES (2) ES2657344T3 (es)
HK (1) HK1202055A1 (es)
HR (2) HRP20150900T1 (es)
HU (2) HUE036265T2 (es)
IL (1) IL233137A0 (es)
LT (1) LT2907521T (es)
MX (2) MX353074B (es)
NO (1) NO2907521T3 (es)
PL (2) PL2672984T3 (es)
PT (2) PT2672984E (es)
RS (2) RS56893B1 (es)
SG (2) SG11201402585PA (es)
SI (2) SI2672984T1 (es)
SM (1) SMT201500201B (es)
TR (1) TR201802360T4 (es)
WO (1) WO2013092776A1 (es)
ZA (1) ZA201403753B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2672984E (pt) 2011-12-19 2015-10-01 Wacker Chemie Ag Novos mutantes de prongf e suas utilizações na produção de beta-ngf
US20160220639A1 (en) * 2013-09-11 2016-08-04 New York University Methods and compositions for treating bone diseases
EP3406259A1 (en) 2017-05-24 2018-11-28 Dompé farmaceutici S.p.A. Neurotrophins for use in the treatment of hearing loss
CN108456681B (zh) * 2018-03-26 2019-10-11 江苏中新医药有限公司 高效表达重组人神经生长因子的基因组合
WO2019207106A1 (en) 2018-04-27 2019-10-31 Chiesi Farmaceutici Spa Production of nerve growth factor (ngf) and of muteins thereof
AU2019293579A1 (en) * 2018-06-29 2021-01-07 The Doshisha Formulation containing emricasan
EP3852785A1 (en) 2018-09-17 2021-07-28 Chiesi Farmaceutici S.p.A. Agent for treatment of dermatological disorders
IT201900014646A1 (it) * 2019-08-12 2021-02-12 Consiglio Nazionale Ricerche Peptide neurotrofico resistente alle proteasi per il trattamento terapeutico di patologie neurodegenerative e/o cutanee
MX2022002833A (es) * 2019-09-17 2022-04-06 Chiesi Farm Spa Agente para usarse en el tratamiento o prevencion de trastornos oftalmicos.
IL302317A (en) 2020-10-28 2023-06-01 Dompe Farm Spa Pharmaceutical packaging including polypropylene containers and aqueous formulations of NGF packed in them
EP4039269A1 (en) 2021-02-05 2022-08-10 Dompe' Farmaceutici S.P.A. Ngf isoform for use in the treatment of ocular pathologies
WO2022221351A1 (en) 2021-04-13 2022-10-20 Dompé Farmaceutici S.P.A. Treatment of neuropathic corneal pain with ngf
EP4311554A1 (en) 2022-07-29 2024-01-31 Dompé farmaceutici S.p.a. Combination for use in ophthalmology
EP4316505A1 (en) 2022-08-05 2024-02-07 Dompé farmaceutici S.p.a. Intranasal administration of ngf for the treatment of sensorineural hearing loss
EP4342485A1 (en) 2022-09-23 2024-03-27 Dompe' Farmaceutici S.P.A. Ngf for the treatment of spasticity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4139000A1 (de) * 1991-11-27 1993-06-03 Boehringer Mannheim Gmbh Verfahren zur gentechnologischen herstellung von biologisch aktivem ss-ngf
ATE257514T1 (de) 1998-10-09 2004-01-15 Scil Proteins Gmbh Verfahren zur gewinnung von aktivem beta-ngf
US20030040082A1 (en) 2001-02-16 2003-02-27 Mark Tuszynski Mutant pro-neurotrophin with improved activity
EP1575477B1 (en) 2001-05-25 2012-04-25 Cornell Research Foundation, Inc. HIGH AFFINITY LIGAND FOR p75 NEUROTROPHIN RECEPTOR
DE10360483B4 (de) 2003-12-22 2007-11-15 Scil Proteins Gmbh Expressionsvektor und dessen Verwendung
WO2005068498A2 (en) 2004-01-19 2005-07-28 Nsgene A/S Human therapeutic cells secreting nerve growth factor
US20080050776A1 (en) 2006-05-26 2008-02-28 Kenneth Neet Stable mutated pro nerve growth factors
CN101260398B (zh) 2007-03-07 2013-06-05 舒泰神（北京）生物制药股份有限公司 神经生长因子基因定位改造动物及其制备方法和应用
PT2672984E (pt) 2011-12-19 2015-10-01 Wacker Chemie Ag Novos mutantes de prongf e suas utilizações na produção de beta-ngf

Also Published As

Publication number Publication date
KR20160120788A (ko) 2016-10-18
SG10201605028VA (en) 2016-07-28
DK2907521T3 (en) 2018-03-05
PT2672984E (pt) 2015-10-01
EP2907521B1 (en) 2017-11-22
CA2859262C (en) 2021-04-06
JP2019006781A (ja) 2019-01-17
NO2907521T3 (es) 2018-04-21
HRP20180307T1 (hr) 2018-03-23
CN104203264A (zh) 2014-12-10
HUE027245T2 (en) 2016-10-28
MX370861B (es) 2020-01-08
PT2907521T (pt) 2018-02-22
US20200031893A1 (en) 2020-01-30
HUE036265T2 (hu) 2018-06-28
ZA201403753B (en) 2015-11-25
EA031333B1 (ru) 2018-12-28
JP2019011330A (ja) 2019-01-24
BR112014014913B1 (pt) 2020-12-01
SI2672984T1 (sl) 2015-11-30
HK1202055A1 (en) 2015-09-18
JP6039146B2 (ja) 2016-12-07
CN109400693A (zh) 2019-03-01
LT2907521T (lt) 2018-05-10
WO2013092776A1 (en) 2013-06-27
JP6622683B2 (ja) 2019-12-18
US9617322B2 (en) 2017-04-11
NZ627054A (en) 2015-06-26
ES2657344T3 (es) 2018-03-02
BR112014014913A2 (pt) 2017-06-13
PL2907521T3 (pl) 2018-04-30
AU2012357052A1 (en) 2014-07-24
HRP20150900T1 (hr) 2015-10-09
RS54220B1 (en) 2015-12-31
CY1119926T1 (el) 2018-12-12
EA201491155A1 (ru) 2015-01-30
CA2859262A1 (en) 2013-06-27
SG11201402585PA (en) 2014-10-30
AU2012357052B2 (en) 2015-06-25
MX2014007317A (es) 2014-11-25
US10308694B2 (en) 2019-06-04
EP2907521A1 (en) 2015-08-19
ES2545701T3 (es) 2015-09-15
SMT201500201B (it) 2015-10-30
US20160244496A1 (en) 2016-08-25
RS56893B1 (sr) 2018-04-30
US20150087020A1 (en) 2015-03-26
DK2672984T3 (en) 2015-08-24
SI2907521T1 (en) 2018-03-30
KR20140103318A (ko) 2014-08-26
PL2672984T3 (pl) 2015-10-30
CY1117016T1 (el) 2017-04-05
TR201802360T4 (tr) 2018-03-21
KR101837802B1 (ko) 2018-03-12
EP2672984A1 (en) 2013-12-18
JP2015501828A (ja) 2015-01-19
IL233137A0 (en) 2014-07-31
CN104203264B (zh) 2018-08-28
EP2672984B1 (en) 2015-05-27
JP2017071611A (ja) 2017-04-13

Similar Documents

Publication Publication Date Title
MX370861B (es) Mutantes profactor de crecimiento del nervio (ngf) novedosos y usos de los mismos en la producción de factor de crecimiento del nervio beta.
MX2011011130A (es) Proteina o peptido de fusion con vida media in vivo incrementada mantenido por liberacion in vivo sostenida, y metodo para incrementar la vida media in vivo usando el mismo.
MX2012000973A (es) Compuestos para la reduccion de produccion de beta- amiloide.
MY155569A (en) Recombinant cells producing ? - aminocarboxylic acid ? - aminocarboxylic acid esters or their lactams
EA201170879A1 (ru) Полипептиды с ксиланазной активностью
NZ593550A (en) ANTI-Siglec-15 ANTIBODY
IN2014DN09922A (es)
PE20141727A1 (es) Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas
GT201300253A (es) Preparacion de gadobutrol de alta pureza
PE20120358A1 (es) Mutantes fgf21 y usos de los mismos
TW200613287A (en) Process for the preparation of 4-(benzimidazolylmethylamino)-benzamidines
HK1132011A1 (en) A method of producing biologically active polypeptide having insulinotropic activity
PH12014502004A1 (en) An improved process for preparation of physiologically active polypeptide complex
MY192981A (en) Cyclosporine analogue molecules modified at amino acid 1 and 3
SG10201902596TA (en) Novel methods of protein evolution
WO2006128764A3 (en) Process for cultivating animal cells comprising the feeding of plant-derived peptones
NZ742660A (en) Variants of chymosin with improved milk-clotting properties
WO2010149578A3 (en) Novel biphenyl and phenyl-pyridine amides
TW200505939A (en) Process for production of cyclic peptides
MX2012007603A (es) Macromolecula para el suministro de farmacos de proteina, polipeptido o peptido y un metodo de produccion para la misma, y una composicion de liberacion lenta para farmacos de proteina, polipeptido o peptido y un metodo de produccion para la misma.
MX2019013801A (es) Compuestos de citocina inhibidora de macrofagos-1 (mic-1) y usos de estos.
MY189932A (en) Recombinant microorganism for improved production of alanine
PH12020550976A1 (en) Camp receptor protein variant and method of producing l-amino acid using the same
WO2011073925A3 (en) C. histolyticum recombinant collagenases and method for the manufacture thereof
MY169049A (en) Microorganisms for producing putrescine and process for producing putrescine using them

Legal Events

Date Code Title Description
FG Grant or registration